NeoGenomics Laboratories

NeoGenomics Laboratories offers a comprehensive portfolio of over 650 diagnostic tests, covering all key testing methodologies, including broad-panel DNA and RNA-based next-generation sequencing. The company provides a variety of comprehensive and targeted approaches to drive precision medicine decisions, particularly in patients with lung cancer. NeoGenomics operates a network of CAP-accredited, CLIA-certified facilities in the U.S. and global laboratories, including locations in Fort Myers, Tampa, Aliso Viejo, Carlsbad, San Diego, Research Triangle Park, Houston, Atlanta, Nashville, and Phoenix. The company also provides a mobile phlebotomy program for liquid biopsy testing at no cost to patients and offers a patient financial assistance program based on federal poverty guidelines. NeoGenomics partners with pharmaceutical clients in clinical trials and drug development, providing a comprehensive oncology-focused testing menu for physicians to help diagnose and treat cancer. Key offerings include the InVisionFirst®-Lung liquid biopsy, a focused 37-gene panel for advanced non-small cell lung cancer (NSCLC), and the Neo Comprehensive™ – Heme Cancers test, which analyzes 433 genes associated with most hematologic malignancies. Other notable tests include the Neo Comprehensive™ - Solid Tumor test, covering 517 cancer-relevant genes, the NeoTYPE® DNA & RNA – Lung test, a targeted tissue-based assay featuring RNA-based fusion detection, and the Neo Comprehensive Myeloid Disorders test, a DNA & RNA next-generation sequencing comprehensive genomic profile analyzing 164 genes relevant in myeloid neoplasms. The company also offers the Early-stage NSCLC Panel, the first and only therapy selection panel designed specifically for early-stage NSCLC patients, as well as NeoAccess™ and NeoSeek™ technology solutions. Additionally, NeoGenomics provides the COMPASS® Hematopathology Services, a streamlined, board-certified hematopathologist-directed approach for complex hematologic malignancies, the CancerTYPE ID® test for identifying the tissue of origin in patients with metastatic cancer, and the Hereditary Cancer test, which includes a comprehensive panel for hereditary cancer syndromes. NeoGenomics also publishes the NeoNEWS newsletter for updates on tests, research, events, and publications.